Quality of life and comorbidity index in patients with arterial hypertension and comorbidities

Mamedov M.N.; Mardanov B.U.; Akhmedova E.B.

doi:https://doi.org/10.17116/profmed20232602156

Mamedov M.N.

National Medical Research Center for Therapy and Preventive Medicine

Mardanov B.U.

National Medical Research Center for Preventive Medicine

Akhmedova E.B.

National Medical Research Center for Therapy and Preventive Medicine

Quality of life and comorbidity index in patients with arterial hypertension and comorbidities

Authors:

Mamedov M.N., Mardanov B.U., Akhmedova E.B.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2023;26(2): 56‑62

DOI: 10.17116/profmed20232602156

Read: 2348 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Mamedov MN, Mardanov BU, Akhmedova EB. Quality of life and comorbidity index in patients with arterial hypertension and comorbidities. Russian Journal of Preventive Medicine. 2023;26(2):56‑62. (In Russ.)
https://doi.org/10.17116/profmed20232602156

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study quality of life and comorbidity index in patients with arterial hypertension and comorbidities.

MATERIAL AND METHODS

The study included 110 patients of both sexes aged 30—69 years with arterial hypertension (AH) and one of two chronic non-communicable diseases (CNCDs): type 2 diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) in remission. All patients were divided into three groups: AH patients (Group 1, n=40, mean age 56.4±8.80 years), AH and type 2 DM (Group 2, n=35, 60.91±5.39 years), AH and COPD (Group 3, n=35, 58.97±8.23 years). Quality of life was assessed using the European questionnaire EQ-5D-3L. The comorbidity index was determined using the Charlson Comorbidity Index.

RESULTS

The EQ-5D-3L questionnaire showed that quality of life was reduced in patients with AH and type 2 DM and with AH and COPD due to components «mobility», «pain/discomfort», and «anxiety/depression». Assessment by EQ visual analog scale showed that when comparing data of Group 1 patients (AH), Group 2 (AH and type 2 DM) and Group 3 (AH and COPD) self-rated health was statistically significantly higher in Group 1 patients without comorbidity (75.63±11.86 points, 67.71±9.80 points, 73.86±9.16 points, p<0.001). Analysis of the predicted 10-year survival in AH patients using the Charlson Comorbidity Index demonstrated that very high comorbidity (21% survival rate) was more common among males (n=14) and females (n=15) in Group 2 (AH and type 2 DM). Male (n=6) and female (n=5) patients with high comorbidity (53% survival rate) were identified in Group 3 (AH and COPD). Moderate (77% survival) and low (over 90% survival) comorbidity were the least common.

CONCLUSION

Concomitant type 2 diabetes mellitus and chronic obstructive pulmonary disease adversely affected the patients with arterial hypertension, reduced quality of life, and worsened 10-year survival prognosis.

Keywords:

quality of life

comorbidity index

arterial hypertension

diabetes mellitus

chronic obstructive pulmonary disease

chronic bronchitis

Authors:

Mamedov M.N.

National Medical Research Center for Therapy and Preventive Medicine

Mardanov B.U.

National Medical Research Center for Preventive Medicine

Akhmedova E.B.

National Medical Research Center for Therapy and Preventive Medicine

Received:

14.09.2022

Accepted:

06.10.2022

Close metadata

References:

World Health Statistics 2016: Monitoring Health for the SDGs. Geneva: World Health Organization.2016.
Lim SS, Vos T, Flaxman AD, Atkinson C, Carnahan E, Colson KE, Engell RE, Freedman G, Freeman MK, Gakidou E, Jasrasaria R, Lozano R, Mallinger L, Mokdad AA, Murphy T, Naghavi M, Roberts T, Rosenfeld LC, Sanman E, Straney L. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260. https://doi.org/10.1016/S0140-6736(12)61766-8
Shalnova SA, Deev AD, Balanova YuA, Kapustina AV, Imaeva AE, Muromtseva GA, Kiseleva NV, Boytsov SA. Twenty-year trends of obesity and arterial hypertension and their associations in Russia. Kardiovaskulyarnaya terapiya i profilaktika. 2017;16(4):4-10. (In Russ.). https://doi.org/10.15829/1728-8800-2017-4-4-10
Bojcov SA, Pogosova NV, Bubnova MG, Drapkina OM, Gavrilova NE, Eganyan RA, Kalinina AM, Karamnova NS, Kobalava ZhD, Koncevaya AV, Kuharchuk VV, Luk’yanov MM, Maslennikova GYa, Marcevich SYu, Metel’skaya VA, Meshkov AN, Oganov RG, Popovich MV, Sokolova OYu, Suhareva OYu, Tkacheva ON, Shal’nova SA, SHestakova MV, Yufereva YuM, Yavelov IS. Cardiovascular prevention 2017. Russian national recommendations. Rossijskij kardiologicheskij zhurnal. 2018;23(6):7-122. (In Russ.).
Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz JJ, Ruiz-Hurtado G, Segura J, Rodríguez-Artalejo F, Williams B. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. New England Journal of Medicine. 2018;378(16):1509-1520. https://doi.org/10.1056/NEJMoa1712231
Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva. World Health Organization; 2009.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of world wide data. Lancet. 2005;365 (9455):217-23. https://doi.org/10.1016/S0140-6736(05)17741-1
Lawes C, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood pressure related disease, 2001. Lancet. 2008; 371(9623):1513-1518. https://doi.org/10.1016/S0140-6736(08)60655-8
Chazova IE, Lazareva NV, Oshchepkova EV. Arterial hypertension and chronic obstructive pulmonary disease: clinical characteristics and effectiveness of treatment (according to the National Register of Arterial Hypertension). Terapevticheskij arhiv. 2019;91(3):4-10. (In Russ.). https://doi.org/10.26442/00403660.2019.03.000110
Ostroumova OD, Kochetkov AI. Chronic obstructive pulmonary disease and comorbid cardiovascular diseases: a view from the perspective of recommendations. Consilium Medicum. 2018;20(1):54-61. (In Russ.).
Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. Diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease (Recommendations of the Russian Medical Society for Arterial Hypertension and the Russian Respiratory Society). Sistemnye gipertenzii. 2013;1:5-34. (In Russ.).
Kim SH, Park JH, Lee JK. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nation wide survey data. Medicine. 2017;96(19):6826. https://doi.org/10.1097/MD.0000000000006826
Nilsson PM, Cederholm J, Zethelius BR, Eliasson BR, Eeg-Olofsson K, Gudbj Rnsdottir S. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Pressure. 2011;20:348-354. https://doi.org/10.3109/08037051.2011.587288
James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansevoort RT, Levey AS, Warnock DG, Sarnak MJ; CKD Prognosis Consortium. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with AKI. American Journal of Kidney Diseases. 2015;66(4):602-612. https://doi.org/10.1053/j.ajkd.2015.02.338
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood Pressure Lowering in Type 2 Diabetes. A Systematic Review and Meta-analysis. JAMA. 2015;313(6):603-615. https://doi.org/10.1001/jama.2014.18574
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-967. https://doi.org/10.1016/S0140-6736(15)01225-8
Snarska K, Chorąży M, Szczepański M, Wojewódzka-Żelezniakowicz M, Ładny JR. Quality of Life of Patients with Arterial Hypertension. Medicina. 2020;56(9):459. https://doi.org/10.3390/medicina56090459
Amirjanova VN, Erdes S. Validation of the Russian version of the general EuroQol 5D questionnaire (EQ-5D). Nauchno-prakticheskaya revmatologiya. 2007;3:69-75. (In Russ.).
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases. 1987;40(5):373-383. https://doi.org/10.1016/0021-9681(87)90171-8
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology. 1992;45(6):613-619. https://doi.org/10.1016/0895-4356(92)90133-8
SAS/STAT User’s Guide. Version 6. Fourth Edition. Vol.1 & 2, SAS Institute Inc., Cary, NC, USA; 1990.
Chesnikova AI, Batyushin MM, Terentyev VP. Arterial hypertension and comorbidity: the current state of the problem. Arterial’naya hypertensiya. 2016; 22(5):432-440. (In Russ.). https://doi.org/10.18705/1607-419X-2016-22-5-432-440
Evdokimova AA, Mamedov MN, Shalnova SA, Deev AD, Tokareva ZN, Yeganyan RA, Oganov RG. Estimating the prevalence of risk factors in a random urban sample of men and women. Profilakticheskaya medicina. 2010; 13(2):3-4. (In Russ.).
Vertkin AL, Skotnikov AS. Comorbidity. Lechashchiy vrach. 2013;8:3-6. (In Russ.).
Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2015;10:95-109. https://doi.org/10.2147/COPD.S54473
Camiciottoli G, Bigazzi F, Magni C, Bonti V, Diciotti S, Bartolucci M, Mascalchi M, Pistolesi M. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2016;11: 2229-2236. https://doi.org/10.2147/COPD.S111724
Kotz D, Simpson CR, Viechtbauer W, van Schayck OC, Sheikh A. Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD. NPJ Primary Care Respiratory Medicine. 2014;24: 140-151. https://doi.org/10.1038/npjpcrm.2014.11
Wong ELY, Xu RH, Cheung AWL. Health-related quality of life among patients with hypertension: population-based survey using EQ-5D-5L in Hong Kong SAR, China. BMJ Open. 2019;9(9):e032544. https://doi.org/10.1136/bmjopen-2019-032544
Balanova YuA, Kontsevaya AV, Shalnova SA, Deev AD, Kapustina AV, Evstifeeva SE, Muromtseva GA, Imaeva AE, Boitsov SA, Gomyranova NV, Konstantinov VV, Mamedov MN, Metelskaya VA, Oganov RG, Suvorova EI, Khudyakov MB, Oschepkova EV, Zhernakova YuV, Konradi AO, Rotar OP, et al. Quality of life of people with arterial hypertension in Russia — Is there a connection with the status of treatment? (According to the population study ESSE-RF). Rossijskij kardiologicheskij zhurnal. 2016;9(137):7-13. (In Russ.). https://doi.org/10.15829/1560-4071-2016-9-7-13
Aristarkhova KN, Mashkantseva MYu, Akimova AV, Kondrashova EV. Komrbidnost’ i vyzhivaemost’ pacientov s arteral’noj gipertenziej i metabolicheskimi narusheniyami. IV Mezhdunarodnaya (74 Vserossijskaya) nauchno-prakticheskaya konferenciya «Aktual’nye voprosy sovremennoj medicinskoj nauki i zdravoohraneniya». Ekaterinburg. 2019;265-270. (In Russ.).